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Abstract
Oxaliplatin is a platinum-based chemotherapeutic used for cancer treatment. Its use associ-
ates with peripheral neuropathies and chronic gastrointestinal side-effects. Oxaliplatin
induces immunogenic cell death by provoking the presentation of damage associated
molecular patterns. The damage associated molecular patterns high-mobility group box 1
(HMGB1) protein exerts pro-inflammatory cytokine-like activity and binds to toll-like recep-
tors (namely TLR4). Gastrointestinal microbiota may influence chemotherapeutic efficacy
and contribute to local and systemic inflammation. We studied effects of oxaliplatin treat-
ment on 1) TLR4 and high-mobility group box 1 expression within the colon; 2) gastrointesti-
nal microbiota composition; 3) inflammation within the colon; 4) changes in Peyer’s patches
and mesenteric lymph nodes immune populations in mice. TLR4+ cells displayed pseudopo-
dia-like extensions characteristic of antigen sampling co-localised with high-mobility group
box 1 -overexpressing cells in the colonic lamina propria from oxaliplatin-treated animals.
Oxaliplatin treatment caused significant reduction in Parabacteroides and Prevotella1, but
increase in Prevotella2 and Odoribacter bacteria at the genus level. Downregulation of pro-
inflammatory cytokines and chemokines in colon samples, a reduction in macrophages and
dendritic cells in mesenteric lymph nodes were found after oxaliplatin treatment. In conclu-
sion, oxaliplatin treatment caused morphological changes in TLR4+ cells, increase in gram-
negative microbiota and enhanced HMGB1 expression associated with immunosuppres-
sion in the colon.
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Introduction
Platinum-based chemotherapeutic agents are widely used for the treatment of cancer, and oxa-
liplatin, the third generation drug, is primarily used as the first-line treatment for colorectal
malignancies [1,2]. Platinum-based drugs mediate their cytotoxic effects via the formation of
nuclear and mitochondrial DNA platinum adducts which ultimately affect cell viability and
hinder prospective replication [3–5]. Despite its therapeutic efficacy, the use of oxaliplatin
causes unfavourable side-effects which include, but are not limited to, peripheral sensory neu-
ropathy and gastrointestinal dysfunction [2,6–9]. These side-effects are major hurdles for can-
cer treatment as they result in dose reductions, treatment non-compliance and cessation
[7,10,11]. Whilst the peripheral sensory neuropathy caused by oxaliplatin has attracted a large
research focus, there are limited studies investigating the effects of this drug on gastrointestinal
dysfunction. Only recently, the enteric nervous system (ENS) has gained attention regarding
its role in the multifaceted pathophysiology of gastrointestinal dysfunction following chemo-
therapeutics [8,9,12]. The ENS is an intrinsic and intricate neuronal network embedded
throughout the gastrointestinal tract which regulates secretion, absorption, vasomotor tone
and motility [13]. The ENS can anatomically be divided into two major plexuses; the submuco-
sal and myenteric. A few studies to date have shown that oxaliplatin induces myenteric neuro-
nal loss, changes in the proportion of neuronal phenotypes, oxidative stress and causes
changes in gastrointestinal transit and motility leading to constipation [8,9,14]. However, the
mechanisms underlying oxaliplatin-induced changes in the myenteric plexus and cell death
remain to be elucidated.
It is well established that anti-cancer agents induce damage to the gastrointestinal mucosa
which may cause dysbiosis of commensal microbiota and potentiate inflammation [15–19]. A
number of studies have reported microbiota dysbiosis following the anti-cancer chemothera-
peutic agents, irinotecan and 5-fluorouracil [20–23]. However, the effects of platinum-based
drugs on gastrointestinal microbiota remain largely unexplored. Gastrointestinal inflamma-
tion has been associated with persistent alterations in enteric neuron function and neuronal
loss [24–26]. The gastrointestinal tract in particular is equipped with lymphoid organs (Peyer’s
patches (PPs) and mesenteric lymph nodes (MLNs)) which houses ~70% of the body’s immu-
nocytes, thus, highlighting their important role in discriminating between innocuous and nox-
ious pathogens or danger signals [27]. Further adding to this complexity, oxaliplatin is
regarded as a potent inducer of immunogenic cell death. Apoptosis has long been considered
to be an immunologically silent or tolerogenic event, however, oxaliplatin treatment has been
shown to induce beneficial anti-cancer immune responses through the induction of damage-
associated molecular patterns (DAMPs) in colorectal cancer cells [28]. The presentation of
DAMPs can prompt the engulfment of dying cells by phagocytes, or apoptotic antigens may be
presented to T cells for targeted elimination [28,29]. A classical DAMP is the nuclear-resident
non-histone protein high mobility group box 1 (HMGB1) which exerts pro-inflammatory
cytokine-like activity once cytoplasmically translocated and/or released into the extracellular
environment by damaged cells [28,29]. HMGB1 is a ligand for toll-like receptors and is pre-
sented to T cells for priming and activation [29,30]. Both DAMPs and pathogen-associated
molecular patterns (PAMPs–microbial endotoxins) can induce an immunological response
following anti-cancer chemotherapy [31,32]. It is unknown whether gastrointestinal inflam-
mation may be implicated in enteric neuropathy associated with oxaliplatin treatment, either
directly or inadvertently.
Herein, we determined the effects of oxaliplatin treatment on 1) TLR4 and HMGB1 expres-
sion within the murine colon; 2) gastrointestinal microbiota composition; 3) inflammation
within the colon; and 4) changes in immune populations within the murine PPs and MLNs. It
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is hypothesized that oxaliplatin treatment will cause gastrointestinal inflammation character-
ized by an increase in TLR4+ and CD45+ cells within the colon lamina propria and at the level
of the myenteric plexus, will cause changes to microbiota composition, and will induce
changes in immune populations within the PPs and MLNs which may contribute to inflamma-
tory enteric neuropathy.
Materials and methods
Animals
Male BALB/c mice (n = 40, aged 7–8 weeks, weighing 18-25g) were used in this study. We
have previously established an orthotopic mouse model of colorectal cancer in Balb/c mice
(35). As cancer and chemotherapy can both differentially affect immune responses, our first
aim is to study them exclusive to one another. We have published several papers on the effects
of chemotherapy on the enteric nervous system using Balb/c mouse models (8, 9, 14). Our pro-
spective studies are to combine colorectal cancer and chemotherapy. Therefore, Balb/c mouse
strain is used in this study. We have based our studies on male mice as fluctuations in hor-
mones during the estrous cycle in female mice may present as confounding factors influencing
immune responses.
Mice had access to food and water ad libitum and were kept under a 12 hour light/dark
cycle in a well-ventilated room at a temperature of 22˚C. Mice acclimatized for up to 1 week
prior to the commencement of in vivo intraperitoneal injections. All efforts were made to min-
imise animal suffering, to reduce the number of animals used, and to utilise alternatives to in
vivo techniques, if available. All procedures in this study were approved by the Victoria Uni-
versity Animal Experimentation Ethics Committee (Animal Ethics number 15–011) and per-
formed in accordance with the guidelines of the National Health and Medical Research
Council Australian Code of Practice for the Care and Use of Animals for Scientific Purposes.
Oxaliplatin treatment
Mice were separated into 2 cohorts (n = 4-10/group): 1) vehicle-treated (sterile water), 2) oxali-
platin-treated (3 mg/kg, Sigma-Aldrich, Australia). All mice received intraperitoneal injections
(volume calculated per body weight, maximum of 200 μl/injection) using 26 gauge needles tri-
weekly totaling 6 injections. Dosages were calculated per body mass as previously published
[33,34]. Mice were culled via cervical dislocation 14 days subsequent to their first intraperito-
neal injection, and the colon, PPs, and MLNs were harvested.
Immunohistochemistry
The colon was harvested (n = 4/group), cut along the mesenteric border and pinned to sili-
cone-based petri dishes containing 1x phosphate buffered solution (PBS). Tissues were incu-
bated in Zamboni’s fixative (2% formaldehyde, 0.2% picric acid and 0.1 M sodium phosphate
buffer (pH 7.0)) overnight at 4˚C. The following day, tissues were washed 3 x 10 minutes in
100% DMSO, followed by 3 x 10 minute washes with 1x PBS. Sections (30μm) were cut and
incubated with a mouse blocking reagent (M.O.M. kit, Vector Labs, USA), or 10% normal
donkey serum for 1 hour at room temperature, then washed 3 x 10 minutes with PBS and Tri-
ton-x100 (PBS-T). Sections were co-labelled with anti-TLR4 (mouse, 1:500, Abcam, USA) and
anti-HMGB1 (rabbit, c-terminus, 1:500, Abcam, USA) antibodies or with anti-CD45 (mouse,
1:500, Abcam, USA) antibody alone. Primary antibodies were incubated at room temperature
overnight, and were then washed 3 x 10 minutes with PBS-T. The secondary antibody for both
TLR4 and CD45 was FITC-conjugated (mouse, 1:200, Abcam, USA) made up in M.O.M.
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diluents; and the secondary antibody for HMGB1 was AlexaFluor-647-conjugated (rabbit,
1:200, Jackson Immuno-Research, USA). Secondary antibodies were incubated at room tem-
perature for 2 hours and then washed 3 x 10 minutes with PBS-T. Sections were mounted onto
glass slides using an anti-fade mounting medium (DAKO, Australia).
Imaging and analysis
Three-dimensional (z-series) images of the colon cross sections were taken using an Eclipse Ti
confocal microscope (Nikon, Japan). Excitation wavelengths were set to 473 nm for FITC and
640.4 nm for Alexa Fluor 647. The number of CD45+ cells was counted from 8 images/prepa-
ration taken at 20x magnification with a total area of 2 mm2. CD45+ immunoreactivity was
measured from 8 images/preparation taken at 20x magnification with a total area of 2 mm2.
All images were captured under identical conditions, calibrated to standardise minimum base-
line fluorescence, and were converted to binary. Differences in fluorescence from baseline
were measured using Image J software (National Institute of Health, USA). All images were
coded and analyzed blindly.
Fecal DNA isolation
Fecal pellets were collected from vehicle- and oxaliplatin-treated animals (n = 10/group), and
stored at -80˚C until time of processing. The PowerFecal DNA Isolation Kit (MO BIO Labora-
ties Inc, Australia) was used to obtain DNA from the fecal pellets as per manufacturer’s
instructions. The isolated fecal DNA was frozen in -80˚C until time of high-throughput
sequence analysis.
PCR amplification of variable regions 3–4 of the 16S rRNA
PCR amplification of variable regions 3–4 (V3–V4) from the 16S rRNA gene and subsequent
Illumina sequencing were performed commercially by the Australian Genome Research Facil-
ity (Brisbane, Australia). The 2-stage PCR protocol was followed according to the Illumina 16S
guidelines (http://sapac.support.illumina.com/downloads/16s_metagenomic_sequencing_
library_preparation.html). Briefly, PCR amplicons were generated using a Forward 341F
primer (CCTAYGGGRBGCASCAG) and a Reverse 806 R primer (GGACTACNNGGGTATC-
TAAT) along with KAPA HiFi HotStart ReadyMix (Roche, Australia). Thermal cycling con-
sisted of 3 min at 95˚C, and 25 cycles consisting of 30 s at 95˚C, 30 s at 55˚C, and 30 s at 72˚C,
followed by 5 min at 72˚C. Second stage PCR was completed by using Nextera XT Index Kit
(Illumina, Australia). Thermal cycling consisted of 3 min at 95˚C, and 8 cycles consisting of 30
s at 95˚C, 30 s at 55˚C, and 30 s at 72˚C, followed by 5 min at 72˚C. Resulting amplicons were
measured by fluorometry, normalised and then pooled with unique indices. This amplicon
pool was then run on the Illumina MiSeq platform.
High-throughput sequence analysis of fecal microbiota
Fecal DNA samples underwent high-throughput sequencing on the Illumina MiSeq platform
at the Australian Genome Research facility (University of Queensland, Brisbane, Australia).
Paired-end reads were assembled by aligning the forward and reverse reads using join_paire-
d_ends.py. Primers were trimmed using Seqtk (version 1.0). Trimmed sequences were pro-
cessed using Quantitative Insights into Microbial Ecology (QIIME 1.9) 4 USEARCH2,3
(version 8.0.1623) software (Caporaso et al. 2010). Briefly, de-multiplexing and quality filtering
were performed using the split_libraries_fastq.py script for each data set. Operational Taxo-
nomic Units (OTUs) were de novo picked at 97% sequence similarity following the usearch
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pipeline and representative sequences of each cluster were used to assign taxonomy through
matching against the Blast 2.2.22 database. Evaluations present at each taxonomic level, includ-
ing percentage compilations, represent all sequences resolved to their primary identification
or their closest relative. Alpha diversity using alpha_diversity.py script was performed for spe-
cies richness, Good’s coverage, Chao1, Shannon-Wiener’s diversity index and Simpson’s index
of diversity. Weighted and unweighted UniFrac distance matrices were obtained through
Jack-knifed beta diversities in QIIME and principal coordinate analysis (PCoA) plots were
obtained. Sample clustering and statistical analysis were carried out in R environment and
SPSS (version 23).
Myeloperoxidase activity
Colon tissues from vehicle- and oxaliplatin-treated animals (n = 3/group) were harvested and
homogenized in 4 volumes of MPO assay buffer using a FastPrep24TM5G homogenizer and
matrix D lysing tubes (MP Biomedicals, Australia) for 40 seconds. The supernatant was trans-
ferred into collecting tubes, and centrifuged at 13,000 x g for 10 minutes at 4˚C. Tissue protein
levels were quantified using the bicinchoninic acid (BCA) assay (Thermo Scientific, Australia)
according to manufacturer’s instructions and absorbance was read at 526 nm using a Varios-
kanTM Flash Multimode Reader (Thermo Scientific, Australia) using SkanIt software v.2.4.3.
The MPO Colorimetric Activity Assay (Sigma-Aldrich, Australia) protocol was followed as per
manufacturer’s instructions. Briefly, TNB standards, MPO positive and negative controls and
each sample was assayed in triplicate. Samples were normalized to protein content. Absor-
bance was read at 412 nm using a VarioskanTM Flash Multimode Reader (Thermo Scientific,
Australia) using SkanIt software v.2.4.3. All standards and samples were corrected for back-
ground absorbance readings. A standard curve plotted and the amount of TNB consumed by
the enzyme assay for each sample was determined. MPO activity was calculated as per manu-
facturer’s instructions: MPO Activity = B Sample Dilution Factor/(Reaction Time) x V. MPO
activity is reported as nmol/min/mL = milliunit.
RNA isolation and RT2 profiler PCR arrays
Colons from vehicle (n = 5) or oxaliplatin-treated (n = 4) mice were removed, snap frozen in
liquid nitrogen and stored in -80˚C until used. Total RNA was extracted using TRIzol (Invitro-
gen, Carlsbad, California) and further purified using an RNeasy Mini kit (Qiagen, Hilden, Ger-
many), including the on-column DNase digestion step. RNA integrity was determined with an
Agilent 2100 Bioanalyzer (Agilent Technologies, USA) using RNA 6000 Nano chips (Agilent
Technologies); RNA Integrity Numbers (RIN) of all colon RNA samples were within an appro-
priate range (vehicle treated: 8.8 ± 0.9, n = 5; oxaliplatin-treated: 9.2 ±0.1, n = 4). Total RNA
concentration was determined on a Qubit Fluorometer (Invitrogen) using a Qubit RNA BR
Assay. Gene expression was investigated using the pathway specific RT2 Profiler PCR Array
‘Mouse Cancer Inflammation and Immunity Crosstalk’ (Qiagen, Cat. no. PAMM-181Z)
according to the manufacturer’s instructions. Arrays were performed using equal quantities of
either vehicle or oxaliplatin-treated RNA. Reverse transcription was carried out with the RT2
First Strand Kit (Qiagen) using 0.5μg pooled RNA as template. Equal amounts of cDNA were
distributed to each well of the RT2 Profiler Array and real-time PCR was performed in a Biorad
CFX96 real-time thermal cycler, using RT2 SYBR Green qPCR Mastermix (Qiagen). PCR
cycling comprised an initial denaturation step at 95˚C for 10 minutes followed by 40 cycles of
95˚C for 15 seconds and 60˚C for 1 minute. Melt curve analysis was performed to verify PCR
specificity. Arrays were performed in duplicate for each RNA pool. CT values (cycle number at
which fluorescence crosses a defined threshold) were obtained using the Bio-rad CFX Manager
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software, using a constant value across all arrays. The detection limit was set at CT of 35 cycles.
CT values were uploaded to and analysed using the web-based Gene Globe Data Analysis Cen-
ter (Qiagen). Data were normalised to the mean of five reference genes: Glyceraldehyde-
3-phosphate dehydrogenase, Gapdh; Beta-2 microglobulin, B2m; Actin-beta, Actb; Glucuroni-
dase-beta, Gusb and Heat shock protein 90 alpha (cytosolic), class B member 1, Hsp90ab1.
Fold change was calculated using the ΔΔCT method, as the ratio of normalised gene expression
in the oxaliplatin-treated group to normalised gene expression in the vehicle-treated control
group.
Flow cytometry
To identify immune cell changes following oxaliplatin treatment the PPs and MLNs were har-
vested. An n = 5 PPs or MLNs were collected from each animal. PPs and MLNs were placed in
15 mL tubes containing FACS buffer (PBS, 0.1% bovine serum albumin and 0.02% sodium
azide) and were kept on ice. Mucosal epithelium lining the PPs and excess adipose tissue
attached to MLNs were gently removed using forceps. Manual cell suspensions of the PPs,
MLNs and spleen were performed. All samples were then centrifuged at 1500 rpm for 5 min-
utes at 4˚C. The supernatant of each cell suspension was aspirated and the pellet containing
the immune cells was then resuspended in 1 mL of FACS buffer and filtered. Manual cell
counts were performed, and cells were seeded to 96 U-bottom well plates (BD Biosciences,
USA) and centrifuged at 1300 rpm for 3 minutes at 4˚C. Subsequent to centrifugation, the 96
U-bottom well plates were then aspirated. A selection of cell surface antibodies was used to
identify various immune cell populations (Table 1). Each antibody cocktail was loaded to
appropriate wells, and incubated for 20 minutes at 4˚C. Subsequent to the incubation period,
the cells were washed with FACS buffer and centrifuged at 1300rpm for 3 minutes at 4˚C. The
plates were aspirated and cells within each well were resuspended in FACS buffer, and then
transferred to FACS tubes. BD Biosciences LSR II and FACS CANTO II flow cytometers were
used to collect 200,000 cells from each cell suspension. Information was obtained via software
FACSDiva (BD Biosciences, USA), and analysis was conducted using FlowJo (Tree Star, USA)
or FACSDiva.
Statistical analysis
For microbiota studies, two-tailed t-tests were used to compare two sets of data, assuming
unequal variance. The data generated by mass spectral analyses were normalized with respect
to internal standards (RSD = 19.28%), where a magnitude of 1 fold change referred to the con-
centration of 10 mg/L. Statistical analysis was performed using SIMCA 14 (Umetrics AG,
Umeå, Sweden). Statistical analysis for all other experiments included an unpaired t-test with
Welch’s correction using GraphPad PrsimTM v6.0 (GraphPad Software, USA). The data were
represented as mean ± standard error of the mean (SEM). Statistical significance for all experi-
ments was defined where the P value was less than 0.05.
Results
Animal symptoms
During the course of oxaliplatin treatment, mice failed to gain weight compared to their con-
trol counterparts, and display signs of nausea (pica), as well as constipation.
Oxaliplatin-induced changes in the gut
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Oxaliplatin treatment causes morphological changes in TLR4+ cells and
reduces TLR7, TLR9 and H2-D1 expression in the colon
Colon cross-sections from the vehicle and oxaliplatin-treated groups were double-labelled
with anti-TLR4 and anti-HMGB1 antibodies to determine any expressional changes. Intense
HMGB1 expression within the lamina propria of the colon from the oxaliplatin-treated ani-
mals was noted when compared to the vehicle-treated cohort (Fig 1A–1B00). Furthermore, co-
localization of TLR4 and HMGB1 was observed in the lamina propria following oxaliplatin
treatment when compared to the vehicle-treated cohort (Fig 1A–1B00; yellow arrows). There
were no differences in the total number of TLR4+ cells between the vehicle-treated (1010 ± 85)
and oxaliplatin-treated groups (1077 ± 87), n = 4-5/group (Fig 1C). Furthermore, no changes
in the total TLR4+-immunoreactivity amongst vehicle-treated (1.7 ± 0.1) and oxaliplatin-
treated cohort (1.8 ± 0.2), n = 4-5/group (Fig 1D) were demonstrated.
TLR4+ cells within the vehicle-treated cohort display minimal contact/co-localisation with
HMGB1 (Fig 2A–2A00). Whereas, TLR4+ cells co-localising with HMGB1 within the lamina
proporia from oxaliplatin-treated group displayed pseudopodia-like extensions characteristic
of antigen sampling (Fig 2B–2B00).
Similar to the lamina propria, there was strong HMGB1 immunoreactivity within the
LMMP of the colon from the oxaliplatin-treated group when compared to the vehicle-treated
cohort (Fig 3A–3B00). However, no TLR4+ cells infiltrated the LMMP layer of the colon follow-
ing either treatment (white arrow; n = 4/group).
Interestingly, oxaliplatin treatment induced down-regulation of TLR7 mRNA expression
(-1.81 fold change) and TLR9 (-2.01 fold change) when compared to the vehicle-treated group
(Fig 4). No changes in TLR2, TLR3 or TLR4 expression were noted following oxaliplatin treat-
ment (Fig 4). In addition, oxaliplatin treatment was associated with reduced expression of
Histocompatibility 2, D region locus 1 (H2-D1; -2.23 fold change) when compared to the vehi-
cle-treated group, however H2-D1 mRNA expression was low in both groups (CT 33 cycles).
Oxaliplatin treatment has no effect on richness, diversity and evenness of
intestinal microbiota, but causes changes at the genus level
To compare compositional differences in the gut microbiota amongst vehicle-treated and oxa-
liplatin-treated mice, 16S rRNA sequencing was conducted. Total DNA was isolated from
Table 1. Antibodies used for FACS experiments.
Cells Primary antibody Conjugate Host species Dilution
Pan-leukocyte marker CD45 PerCP/Cy5.5 Mouse 1:400
Pan-T cell marker CD3 PerCP/Cy5.5 Mouse 1:400
T cell receptor TCRβ APC Rat 1:250
Granulocytes GR-1, CD11b PE-Cy7 Rat 1:100
Cytotoxic T cells CD8 Pacific Blue Rat 1:100
Helper T cells CD4 Pacific Orange Rat 1:100
B cells B220 FITC Mouse 1:400
Macrophages CD11b, Ly6C, Ly6G, CD206, F4/80 PE Rat 1:200
Dendritic cells CD11c Pacific Blue Rat 1:250
Major histocompatibility complex II MHC-II Brilliant Violet 510 Rat 1:800
Eosinophils CD193 Alexa Fluor 647 Rat 1:200
NK cells CD49b PE Rat 1:100
γδ T cells γδ-TCR FITC Mouse 1:500
NKT cells CD1d α-Galactosylceramide tetramer PE Rat 1:500
https://doi.org/10.1371/journal.pone.0198359.t001
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Fig 1. Effects of oxaliplatin treatment on HMGB1 expression and co-localisation with TLR4 in the lamina propria of the colon. Colon cross-sections (30μm
thick) from the vehicle and oxaliplatin-treated groups were labelled with anti-TLR4 (green) and anti-HMGB1 (magenta) antibodies (A-B0 0). Strong HMGB1
immunoreactivity is observed within the lamina propria (B0) of the colon from the oxaliplatin-treated animals when compared to the vehicle-treated cohort (A0).
Greater co-localisation of TLR4 and HMGB1 is evident within the lamina propria (B0 0) following oxaliplatin treatment when compared to the vehicle-treated
cohort (A0 0). The numbers of TLR4+ cells were counted from 8 images per preparation taken at 20x magnification with a total area of 2mm2. No differences in the
total number (C), or TLR4+ immunoreactivity (D) was observed following oxaliplatin treatment when compared to the vehicle group. Scale = 10μm; n = 4-5/
group.
https://doi.org/10.1371/journal.pone.0198359.g001
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Fig 2. Changes in TLR4+ cell morphology and interaction with HMGB1 in the lamina propria of the colon
following oxaliplatin treatment. Colon cross-sections (30μm thick) from the vehicle (A) and oxaliplatin-treated (B)
mice were labelled with anti-TLR4 (green) and anti-HMGB1 (magenta) antibodies and presented as 3D reconstruction
of confocal z-series slices. TLR4+ cells within the lamina propria of the colon from the oxaliplatin-treated animals form
contacts with HMGB1 through extending processes (B0-B0 0, insets with yellow arrows), as opposed to the spherical
morphology of TLR4+ cells in the vehicle-treated cohort (A0-A0 0, insets), n = 4/group.
https://doi.org/10.1371/journal.pone.0198359.g002
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fecal samples (n = 10 mice/group), and PCR amplicons spanning the 16S rRNA V3-V5 hyper-
variable region were sequenced. Microbiota composition was assessed with regards to opera-
tional taxonomic units (OTUs) Chao richness, Shannon diversity index, Simpson’s diversity
index, as well as unweighted UniFrac Principal Coordinate Analysis (PCoA).
No significant difference in the numbers of OTUs was observed between the vehicle-treated
(3058 ± 233.6) and the oxaliplatin-treated mice (3134 ± 175.6) (Fig 5A). Furthermore, no sig-
nificant difference in Chao richness was observed amongst the vehicle-treated (3058 ± 233.6)
Fig 3. Effects of oxaliplatin treatment on HMGB1 expression and co-localisation with TLR4 in the longitudinal
muscle-myenteric plexus (LMMP) of colon. Colon cross-sections (30μm thick) from the vehicle and oxaliplatin-
treated groups were labelled with anti-TLR4 (green) and anti-HMGB1 (magenta) antibodies (A-B0 0). No TLR4+ cells
infiltrated the level of the LMMP in either group (A, B).Strong HMGB1 immunoreactivity is observed within the colon
from the oxaliplatin-treated animals (B0) when compared to the vehicle-treated cohort (A0). Scale = 10μm; n = 4/
group.
https://doi.org/10.1371/journal.pone.0198359.g003
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and the oxaliplatin-treated cohort (3562 ± 381.5) (Fig 5B). There were no significant differ-
ences in diversity between the vehicle-treated (0.97 ± 0.002) and the oxaliplatin-treated group
(0.971 ± 0.003) (Fig 5C). Principle coordinate analysis (PCOA) from oxaliplatin-treated mice
microbiome based upon unweighted UniFrac distance did not show significant difference
when compared to the vehicle-treated cohort (Fig 5D).
In this study, five major phyla groups were identified: Bacteroidetes, Deferribacteres, Firmi-
cutes, Proteobacteria and Tenericutes. Although Bacteroidetes was the most abundant phylum
species, no significant differences were observed between the vehicle-treated (88.3 ± 1.2) and
oxaliplatin-treated mice (84.9 ± 2.2) (Fig 5E). No significant differences in Deferribacteres
phyla were observed amongst the vehicle-treated (0.45 ± 0.25) and the oxaliplatin-treated
cohort (0.40 ± 0.16) (Fig 5F) as well as to Firmicutes (1.14 ± 0.15; vehicle treated) compared to
(1.35 ± 0.29; oxaliplatin-treated group) (Fig 5G). In addition, there were no significant changes
to Proteobacteria abundance following oxaliplatin treatment (1.35 ± 0.29) compared to vehi-
cle-treatment (1.14 ± 0.15) (Fig 5H). Furthermore, no changes in Tenericutes phyla were
observed amongst the vehicle-treated (0.03 ± 0.009) and oxaliplatin-treated mice (0.04 ± 0.01)
(Fig 5I).
Changes to the composition of the microbiota genera following oxaliplatin treatment was
determined using 16S rRNA sequencing. Twelve common species present in both the vehicle-
treated and the oxaliplatin-treated cohort were identified. These species included: Bacteroides,
Parabacteroides, Prevotella1, Prevotella2, Odoribacter, Mucispirillum, Lactobacillus, Dehalobac-
terium, Ruminococcus, Sutterella, Bilophila and Desulfovibrio. The particular taxonomy for Pre-
votella1 and Prevotella2 is yet to be determined. Unknown species ‘unknown’ were also
detected in both the vehicle-treated and the oxaliplatin-treated cohorts (Table 2). A significant
reduction in Parabacteroides (vehicle-treated: 0.71 ± 0.003; oxaliplatin-treated: 0.21 ± 0.04;
P<0.0001) and Prevotella1 species (vehicle-treated: 1.06 ± 0.002; oxaliplatin-treated:
0.64 ± 0.13; P<0.05) was noted in the oxaliplatin-treated group when compared to the vehicle-
treated cohort (Fig 5J and 5K, Table 2). Oxaliplatin treatment induced a significant increase
in the Prevotella2 species (vehicle-treated: 4.87 ± 0.01; oxaliplatin-treated: 8.58 ± 1.4; P<0.05)
and in the Odoribacter species (vehicle-treated: 0.39 ± 0.0007; oxaliplatin-treated: 0.62 ± 0.08;
Fig 4. Effects of oxaliplatin treatment on mRNA expression immune receptors. To determine whether oxaliplatin
treatment induced changes in the expression of receptors within the colon, RT2 Profiler PCR arrays were performed
using pooled RNA samples from (vehicle, n = 5; oxaliplatin, n = 4) samples. Oxaliplatin treatment caused a down-
regulation of TLR7, TLR9 and H2-D1 mRNA expression when compared to the vehicle-treated cohort. No change in
TLR2, TLR3 or TLR4 expression was observed following oxaliplatin treatment.
https://doi.org/10.1371/journal.pone.0198359.g004
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Fig 5. Effects of oxaliplatin treatment on the composition of intestinal microbiota. Fecal microbiota Chao richness estimate, Simpson diversity estimate
and evenness following oxaliplatin treatment were analysed using 16S rRNA sequencing. Oxaliplatin treatment did not cause any significant changes to the
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P<0.05) when compared to the vehicle-treated group (Fig 5L and 5M; Table 2). No changes
to Bacteroides, Mucispirillum, Lactobacillus, Dehalobacterium, Ruminococcus, Sutterella, Bilo-
phila, Desulfovibrio or ‘unknown’ species were shown.
Lack of immune responses in the colon following oxaliplatin treatment
The pan-leukocyte marker anti-CD45 antibody was used to label immunocytes in the colon
(Fig 6A and 6B). There were no differences in the total number of CD45+ cells between the
vehicle-treated (1553 ± 169) and oxaliplatin-treated groups (1666 ± 143), n = 4/group (Fig
6C). No significant changes in CD45+ immunoreactivity to indicate inflammation in the colon
was observed following oxaliplatin treatment (2.08 ± 0.16) when compared to the vehicle-
treated cohort (1.75 ± 0.30), n = 4/group (Fig 6D). Furthermore, no CD45+ immune cells were
found at the level of the myenteric ganglia. MPO is a peroxidase enzyme with antimicrobial
capacity and is typically used as a biomarker for inflammation. No significant difference in
MPO activity was shown between the oxaliplatin-treated (0.093 ± 0.01 nmol/min/mL; n = 4)
and vehicle-treated groups (0.08 ± 0.02 nmol/min/mL), n = 4/group (Fig 6E).
In order to profile changes in gene expression associated with inflammation, RT2 Profiler
PCR arrays of colon RNA were performed using pooled RNA samples. Oxaliplatin treatment
caused the down-regulation of the cytokines interleukin (IL)-1β (-2.02 fold change) and IL-
12β (-3.56 fold change). Reduced interferon gamma mRNA expression (IFN-γ; -1.71 fold
change) was also observed following oxaliplatin treatment, however expression was low
(CT34) in both vehicle and treated groups (Fig 7A). Moreover, oxaliplatin treatment caused
higher mRNA expression of the chemokine ligand Ccl-2 (3.25 fold change) and lower
number of OTUs (A), Chao richness estimate (B), Simpson diversity estimate (C) or PCoA unweighted UniFrac distance percentages (D). Oxaliplatin
treatment did not cause any significant changes to five dominant phyla groups identified in the fecal microbiota: Bacteroidetes (E), Deferribacteres (F),
Firmicutes (G), Proteobacteria (H) and Tenericutes (I). Oxaliplatin treatment caused a significant reduction in Parabacteroides (J) and Prevotella1 (K) species,
and a significant increase in Prevotella2 (L) and Odoribacter species (M). P<0.05; P<0.01; P<0.0001; n = 10/group.
https://doi.org/10.1371/journal.pone.0198359.g005
Table 2. Changes to microbiota at the genus level following oxaliplatin treatment.
Vehicle Oxaliplatin
Mean SEM N Mean SEM N
Bacteroides 5.80 0.012 10 5.56 1.54 10
Parabacteroides 0.71 0.003 10  0.21 0.04 10
Prevotella1 1.06 0.002 10  0.64 0.13 10
Prevotella2 4.87 0.013 10  8.58 1.41 10
odoribacter 0.39 0.0007 10  0.62 0.08 10
Mucispirillum 0.45 0.002 10 0.40 0.18 10
Lactobacillus 1.01 0.002 10 2.28 0.67 10
Dehalobacterium 0.19 0.0004 10 0.17 0.04 10
Ruminococcus 0.01 0.00005 10 0.01 0.00 10
Sutterella 0.36 0.001 10 0.40 0.07 10
Bilophila 0.19 0.0006 10 0.19 0.06 10
Desulfovibrio 0.51 0.001 10 0.71 0.28 10
Unknown 5.68 0.005 10 6.55 0.52 10
P<0.05
P<0.01
P<0.0001. Mean = % abundance; SEM, standard error of the mean
https://doi.org/10.1371/journal.pone.0198359.t002
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Fig 6. Effects of oxaliplatin treatment on the fluorescence and number of CD45+ immune cells, and MPO activity in the
colon. Colon cross-sections (30μm thick) from the vehicle and oxaliplatin-treated groups were labelled with the pan-leukocyte
marker anti-CD45 antibody (green) (A-B: scale bars = 50μm). The numbers of CD45+ cells were counted from 8 images per
preparation taken at 20x magnification with a total area of 2mm2. No significant differences in the total number of CD45+ cells
(C), or immunoreactivity (D) within the colon is observed between the vehicle-treated and oxaliplatin-treated cohorts, n = 4-5/
Oxaliplatin-induced changes in the gut
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expression of Ccl5 (-2.19 fold change) and Ccl22 (-2.63 fold change) (Fig 7B). Lower levels of
activation induced cytidine deaminase, Aicda; (-2.32 fold change) and colony stimulating fac-
tor 2 (Csf2; -1.87 fold change) were also observed following oxaliplatin treatment, however
these genes were also expressed at low levels (CT33) in both vehicle and oxaliplatin-treated
samples. Overall most genes on the array showed no change in mRNA expression in the oxali-
platin-treated group, when compared to the vehicle-treated group (S1 Table).
Oxaliplatin treatment induces changes in immune cell populations within
the MLNs, but not PPs
To determine the effects of oxaliplatin treatment on the gastrointestinal immune response, we
profiled granulocyte and lymphocyte populations within the PPs and MLNs using FACS. Sev-
eral immune cell populations were gated by the following: macrophages (F4/80+ MHC-II+);
dendritic cells (CD11c+ MHC-II+); eosinophils (CD11B+ MHC-II- Gr-1+ CD193+ and
CD11B+ MHC-II+ Gr-1+ CD193+); NK cells (CD49b+ TCR-); γδ T cells (γδ-TCR+ TCRβ-); B
cells (CD45+ TCRβ- B220+); CD4+ T cells (CD4+ TCR+); CD8+ T cells (CD8+ TCR+); NKT
cells (CD1d α-Galcer tetramer+ TCR. Oxaliplatin treatment did not cause any significant
changes to the proportion of immune cells within the PPs when compared to the vehicle-
treated cohort (Fig 8A–8I, Table 3; n = 5/group). However, oxaliplatin treatment resulted in a
significant reduction in the proportion of macrophages and dendritic cells within the MLNs
when compared to vehicle-treated group (Fig 9A and 9B, Table 4). No changes in other
immune cell populations were noted (Fig 9C–9I, n = 5/group).
Discussion
This study is the first to determine the potential for oxaliplatin treatment to induce inflamma-
tory enteric neuropathy within the murine colon. Oxaliplatin is a potent immunogenic cell
death inducer, thus, it was hypothesized that mucosal and neuronal damage would be associ-
ated with an inflammatory response [12,28,29,35]. However, in this study we have shown that
oxaliplatin treatment does not induce inflammation or changes in total TLR4 immunoreactiv-
ity, despite noticeable changes in HMGB1 expression which is a TLR4 ligand. It is well estab-
lished that cytoplasmic and/or released HMGB1 can exert pro-inflammatory cytokine-like
activity capable of inducing strong immunological responses [36,37]. In immunogenic cell
death HMGB1 is passively released and acts as a potent ‘eat me’ signal, however, oxidative
stress and apoptosis can blunt this pro-inflammatory signalling [38–40]. In this study,
HMGB1 and TLR4 co-localisation as well as morphological differences in TLR4+ cells within
the lamina propria, but not in the LMMP following oxaliplatin treatment were observed. The
TLR4+ cells co-localised with HMGB1 show pseudopodia-like morphology which is character-
istic of antigen sampling [41]. Under conventional circumstances, antigen presenting cells
migrate to their nearest draining lymph nodes (such as PPs and MLNs in this case) upon anti-
gen recognition for the priming and activation of T cells. Despite the HMGB1 and TLR4 inter-
action, there was no amplification of immune cell populations within the lymphoid organs
(PPs and MLNs). Presumably, HMGB1 could still be sampled by antigen presenting cells, but
may be regarded as an innocuous/neutral molecule. This is apparent when HMGB1 becomes
oxidized [39,42]. Additionally, the pro-inflammatory effects of HMGB1 are also dependent on
group. To determine whether oxaliplatin treatment caused inflammation within the colon specific to neutrophils or macrophages
a MPO assay was conducted. Oxaliplatin treatment did not induce any significant changes to MPO activity within the colon when
compared to the vehicle-treated cohort (E). N = 4/group.
https://doi.org/10.1371/journal.pone.0198359.g006
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its redox state [43–46]. We have previously shown that oxaliplatin treatment induces oxidative
stress through the upregulation of inducible nitric oxide synthase (iNOS) within the LMMP,
as well as an increase in mitochondrial superoxide production and protein nitrosylation in
myenteric neurons [9]. Given that oxaliplatin induces an oxidative environment, this particu-
lar DAMP may therefore be subjected to oxidisation, and thus, have its inflammatory potential
blunted; this needs further investigation. Moreover, we observed the downregulation of TLR7
and TLR9 following oxaliplatin treatment, with no changes to TLR2, TLR3 or TLR4. TLRs are
membrane-bound receptors which recognise a myriad of ligands produced by microbiota, as
well as DAMPs [47–49]. TLR stimulation by ligands triggers signal transduction pathways and
Fig 7. Effects of oxaliplatin treatment on cytokine and chemokine mRNA expression. To determine whether
oxaliplatin treatment induced changes in inflammatory mediators within the colon, RT2 Profiler PCR arrays were
performed using pooled RNA samples from (vehicle, n = 5; oxaliplatin, n = 4) samples. Oxaliplatin treatment caused
the down-regulation of the cytokines IL-1β, IL-12β mRNA expression when compared to the vehicle-treated group
(A). Oxaliplatin treatment induced the up-regulation of the chemokine Ccl2, and the down-regulation of Ccl5 and
Ccl22 chemokine mRNA expression when compared to the vehicle-treated cohort (B).
https://doi.org/10.1371/journal.pone.0198359.g007
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immunological responses [50,51]. TLR2 recognises bacterial lipoproteins and non-entero-
bacterial LPS [52]. Furthermore, TLR3 recognises double-stranded viral RNA, and TLR4 is
stimulated by classical LPS [53,54]. TLR7 recognises single-stranded viral RNA, whereas TLR9
is stimulated by bacterial and viral DNA [51,55,56]. The downregulation of TLR7 and TLR9
observed in this study would impair recognition of certain pathogens and prospective immune
responses.
Fig 8. Immune cell populations within the PPs from vehicle and oxaliplatin-treated mice. A series of gating strategies were used to identify
immune cell populations within the PPs: macrophages (F4/80+ MHC-II+); dendritic cells (CD11c+ MHC-II+); eosinophils (CD11B+ MHC-II- Gr-
1+ CD193+ and CD11B+ MHC-II+ Gr-1+ CD193+); NK cells (CD49b+ TCR-); γδ T cells (γδ-TCR+ TCRβ-); B cells (CD45+ TCRβ- B220+); CD4+ T
cells (CD4+ TCR+); CD8+ T cells (CD8+ TCR+); NKT cells (CD1d α-Galcer tetramer+ TCR+). No significant differences were observed in any
immune cell types within PPs (A-I), n = 5/group.
https://doi.org/10.1371/journal.pone.0198359.g008
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Moreover, the downregulation of H2-D1 was observed following oxaliplatin treatment. The
H2-D1 gene is associated with MHC-related molecules and antigen presentation. This down-
regulation could impact antigen loading and presentation to effector lymphocytes such as
CD8+ T cells. Oxaliplatin treatment has been shown to evoke changes in another DAMP, calre-
ticulin, a multifunctional endoplasmic reticulum and nuclear envelope-resident protein
[28,57]. A major function for calreticulin is the biogenesis and correct folding and assembly of
MHC-related molecules [58,59]. The downregulation of H2-D1 may be associated with
changes in calreticulin expression which requires further investigation. The lack of gastrointes-
tinal immune responses following oxaliplatin treatment could be due to defective MHC assem-
bly and antigen presentation.
The mammalian gastrointestinal tract is colonised by diverse microorganisms where a sym-
biotic relationship between the host and microbiota exists [60]. The composition of microbiota
throughout the gastrointestinal tract can vary depending on the location. The colon in particu-
lar has the greatest microbial density with an astounding 1x 1012 organisms per gram of feces
(dry weight) [61]. In this study, we isolated fecal DNA and identified five major phyla which
included: Bacteroidetes, Deferribacteres, Firmicutes, Proteobacteria and Tenericutes. Oxaliplatin
did not cause significant changes to the microbiota at the phylum level in terms of OTUs,
Chao richness and diversity, however, induced a significant reduction in Parabacteroides and
Prevotella1 species, but caused an increase in Prevotella2 and Odoribacter. Parabacteroides, Pre-
votella and Odoribacter genera stem from the Bacteroides phylum. The Bacteroides phyla and
their successive genera stem from the Bacteroidetes family. These bacteria are gram-negative,
anaerobic, non-spore-forming rods which are commensal to the gastrointestinal tract, but are
known to be opportunistic pathogens in circumstances of intestinal barrier destruction [62]. It
is well established that anti-cancer agents cause considerable damage to the gastrointestinal
mucosa which can act as a gateway for microbiota-induced inflammation throughout the
colon [10,63,64]. Gram-negative bacteria produce endotoxins such as lipopolysaccharides
(LPS; bacterial cell wall constituents) which can induce immunological responses and contrib-
ute to inflammatory diseases through TLR binding [65–68]. LPS come in ‘classical’ and ‘non-
classical’ forms, depending on its structural configuration and degree of acylation [69–71].
Classical LPS are acylated lipid A molecules on short-chain fatty acids which stimulate a num-
ber of pro-inflammatory responses through cytokine production (predominantly TNF-α and
IL-6) by innate immune cells (neutrophils, monocytes and macrophages) [69,72]. TLR4 is a
main receptor for ‘classical’ LPS produced by Escherichia coli, whereas LPS from Bacteroides
species are considered ‘non-classical’ and thus, TLR binding may not induce a rapid or strong
Table 3. Proportions of various immune cell populations within the PPs following vehicle and oxaliplatin
treatment.
Immune cell population Vehicle Oxaliplatin
Macrophages 1.3 ± 0.1 1.1 ± 0.3
Dendritic cells 2.9 ± 0.3 2.5 ± 0.7
Eosinophils: MHC-II+
MHC-II-
0.8 ± 0.2
0.6 ± 0.1
0.7 ± 0.01
0.7 ± 0.1
NK cells 1.7 ± 0.5 3.3 ± 1.1
γδ T cells 0.7 ± 0.01 0.8 ± 0.04
B cells 53.1 ± 1.4 45.5 ± 3.4
CD4+ T cells 56.0 ± 17.0 52.3 ± 14.8
CD8+ T cells 6.9 ± 1.8 10.1 ± 2.7
NKT cells 0.4 ± 0.1 0.6 ± 0.17
https://doi.org/10.1371/journal.pone.0198359.t003
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immunological response [69,73]. Although structurally similar to classical LPS, the non-classi-
cal version still contains a lipid A centre, however, with varying degrees of acylation, and is
often attached to long-chain fatty acids linked to amino-sugar backbones which is thought to
hinder LPS recognition and signalling [65,69]. The inability to produce potent or classical LPS
by the Bacteroides family, and the lack of changes to total TLR4 immunoreactivity observed in
Fig 9. Immune cell populations within the MLNs from vehicle and oxaliplatin-treated mice. A series of gating strategies were used to identify immune
cell populations within the MLNs: macrophages (F4/80+ MHC-II+); dendritic cells (CD11c+ MHC-II+); eosinophils (CD11B+ MHC-II- Gr-1+ CD193+
and CD11B+ MHC-II+ Gr-1+ CD193+); NK cells (CD49b+ TCR-); γδ T cells (γδ-TCR+ TCRβ-); B cells (CD45+ TCRβ- B220+); CD4+ T cells (CD4+ TCR+);
CD8+ T cells (CD8+ TCR+); NKT cells (CD1d α-Galcer tetramer+ TCR+). Oxaliplatin treatment caused a significant reduction in the proportion of
macrophages and dendritic cells (A, B), with no effects on eosinophils, NK cells, γδ T cells, B cells (CD45+ TCRβ- B220+); CD4+ T cells (CD4+ TCR+);
CD8+ T cells (CD8+ TCR+); NKT cells (CD1d α-Galcer tetramer+ TCR+) within MLNs (C-I). P<0.05, n = 5/group.
https://doi.org/10.1371/journal.pone.0198359.g009
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our present study may explain the absence of inflammation within the colon despite the
increased abundance of such species at the genus level following oxaliplatin treatment.
It is known that immune cells within the gastrointestinal mucosa function differently to
their counterparts found within the circulation. The mucosal immune system has co-evolved
with the gastrointestinal microbiota/antigens and sterile inflammation to downregulate pro-
inflammatory responses whilst uncompromising microbicidal or phagocytic activity [74,75].
No inflammation (determined by CD45+ immune cell infiltrate) or differences in total TLR4
immunoreactivity throughout the thickness of the colon was observed following oxaliplatin
treatment.
There were no noticeable effects on MPO activity within the colon following oxaliplatin
treatment. MPO is a well-established biomarker of inflammation in various conditions such as
multiple sclerosis, ischaemic heart disease and acute coronary syndromes, as well as ulcerative
colitis [76–80]. MPO is a cytotoxic constituent released by activated myeloid cells such as neu-
trophils, which also has micobicidal capacity [81–84]. Despite changes in gastrointestinal
microbiota at the genus level, as well as increased HMGB1 expression which is known to have
pro-inflammatory effects, MPO activity was not altered. Thus, our MPO data provide further
evidence that oxaliplatin does not induce gastrointestinal inflammation, which presumably,
would not have major effects on the colon myenteric plexus.
Furthermore, we demonstrate that oxaliplatin treatment downregulated gene expression
for the pro-inflammatory cytokines IL-1β, IL-12β within the colon. Cytokines can mediate
inflammation and trigger extrinsic apoptotic cascades. Although the extrinsic and intrinsic
apoptotic pathways are considered to be separate entities, there is some cross over between the
two signal transduction pathways [85–87]. Given that pro-inflammatory cytokines are down-
regulated in the colon following oxaliplatin treatment it is unlikely that the extrinsic apoptotic
cascade is implicated in the underlying mechanism of cell death within the myenteric plexus.
It has previously been shown that oxaliplatin treatment does not alter IL-1β, IFN-γ expression
within rat spinal cord and DRG neurons, nor does it induce immune cell infiltration [88].
However, there are some conflicting studies which have demonstrated a significant increase in
pro-inflammatory cytokines IL-1β and TNF-α within the rat spinal cord following oxaliplatin
treatment, and a reduction in the anti-inflammatory cytokines IL-4 and IL-10 [89–91]. In the
aforementioned studies, acute experiments were conducted on rats which were treated with
oxaliplatin through a single 6mg/kg/d, or a 10mg/kg/d for 5 consecutive days. This is in
Table 4. Proportions of various immune cell populations within the MLNs following vehicle and oxaliplatin
treatment.
Immune cell population Vehicle Oxaliplatin
Macrophages 2.8 ± 0.5 1.1 ± 0.2
Dendritic cells 5.1 ± 0.3 2.5 ± 0.1
Eosinophils: MHC-II+
MHC-II-
2.5 ± 0.2
0.8 ± 0.1
2.0 ± 0.2
1.0 ± 0.1
NK cells 0.6 ± 0.1 0.8 ± 0.1
γδ T cells 0.5 ± 0.01 0.5 ± 0.03
B cells 15.3 ± 0.8 14.2 ± 1.7
CD4+ T cells 64.6 ± 6.1 66.0 ± 4.8
CD8+ T cells 20.6 ± 1.6 22.0 ± 0.9
NKT cells 0.8 ± 0.3 0.9 ± 0.3
P<0.05
P<0.001.
https://doi.org/10.1371/journal.pone.0198359.t004
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contrast to our current study where we have chronically treated mice tri-weekly for up to 14
days with a 3mg/kg/d. The differences between oxaliplatin dosage, species and experimental
time points may contribute to varying results.
Furthermore, we showed that the chemokine Ccl2 was upregulated within the colon follow-
ing oxaliplatin treatment. Despite the increase in Ccl2 (a monocyte chemoattractant), there
were no increases in immune cells in the colon. Ccl2 is a pleiotropic ligand implicated in many
pathways. Ccl2 has demonstrated a role in shaping pro-inflammatory/anti-inflammatory mac-
rophage responses as a deficiency leads to skewed pro-inflammatory phenotypes producing
high levels of IL-6 and TNF-α [92]. The upregulation of Ccl2 in the colon following oxaliplatin
treatment may play a role in dampening pro-inflammatory cytokine production by promoting
the polarisation of anti-inflammatory macrophages. Ccl2 is also upregulated in response to
gastrointestinal microbiota [93]. Whether the increase in microbiota species observed in this
study is implicated in Ccl2 upregulation requires further study. Furthermore, previous
research has demonstrated that Ccl2 is upregulated in DRG neurons and microglia following
peripheral nerve injury prompting macrophage infiltration and sensory neuropathy [94–96].
Ccl2 can also be upregulated by other cytokines such as s100β [97]. We have previously dem-
onstrated that s100β expression within the myenteric plexus of the ileum is increased following
oxaliplatin treatment (Robinson et al., 2016). Whether upregulated s100β can impact Ccl2 lev-
els within the colon requires further investigation. In addition, this study demonstrates that
oxaliplatin treatment downregulated Ccl5 and Ccl22. Ccl5 plays a role in lymphocyte traffick-
ing and promoting T cell polarisation towards an IFN-γ-producing Th1 phenotype [98].
Moreover, Ccl22 is implicated in lymphocyte and eosinophil migration [99,100]. The downre-
gulation of Ccl5 and Ccl22 following oxaliplatin treatment may impact lymphocyte and/or
eosinophil migration throughout the colon.
Downregulation of Aicda and Csf2 were also observed following oxaliplatin treatment.
Aicda regulates B cell proliferation and immunoglobulin class switching [101]. In this study
we did not observe any changes to B cell populations within the PPs and MLNs following oxa-
liplatin treatment. It is unknown whether the downregulation of this gene may affect B cell
numbers and function at a later time point. Csf2 is a cytokine involved in macrophage and
granulocyte production and maturation [102,103]. Downregulation of Csf2 is consistent with
the decrease in macrophages and dendritic cells within the MLNs observed in this study.
We investigated the effects of oxaliplatin treatment on the immunological responses within
the PPs and MLNs. PPs contain specialised epithelia known as microfold or M cells which are
pivotal induction sites for pathogen or antigen-specific immune responses [104,105]. Den-
dritic cells within the PPs consistently sample luminal antigens and bacteria, and if loaded
with an inflammatory stimulus, prime local T cells to initiate a response [27,106,107]. Intesti-
nal dendritic cells also migrate to T cell areas of MLNs which is thought to play a role in main-
taining immunological tolerance [108]. Although there were no demonstrable changes to the
proportion of immune populations within the PPs following oxaliplatin treatment, a propor-
tional reduction in both macrophages and dendritic cells within the MLNs was observed.
Immunological responses within the lymph nodes would typically occur once antigen present-
ing cells are antigen-loaded and have migrated to prime T cells to initiate an immune response.
However, no demonstrable changes to T cell populations were observed within the PPs or
MLNs following oxaliplatin treatment.
Furthermore, oxaliplatin treatment did not induce changes to other immune cell popula-
tions investigated in this study which include eosinophils, NK cells, γδ T cells, B cells, CD4+ T
cells, CD8+ T cells and NKT cells, all of which have important roles in maintaining gastrointes-
tinal homeostasis as well as initiating and modulating immune responses.
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Under normal conditions eosinophils reside within haematopoietic and lymphatic tissues,
as well as the gastrointestinal tract mucosa [109,110]. Eosinophils are pro-inflammatory effec-
tor cells which release pleiotropic chemokines, cytokines and cytotoxic granules such as eosin-
ophil peroxidase and eosinophil-derived neurotoxin [111,112]. Eosinophils have been
implicated in a number of inflammatory conditions in the gastrointestinal tract. These include
eosinophilic gastroenteritis, allergic colitis, and inflammatory bowel disease [113–115]. In this
study we did not observe changes in the proportion of eosinophils within the PPs and MLNs
which is consistent with oxaliplatin-induced immunosuppression observed in the colons from
oxaliplatin-treated mice. Thus, eosinophils do not appear to be affected by oxaliplatin treat-
ment, and are unlikely to mediate enteric neuropathy.
Furthermore, no changes in the proportion of NK cells within the PPs and MLNs were
observed following oxaliplatin treatment. NK cells are innate lymphocytes present throughout
the gastrointestinal tract and associated lymphoid organs [116]. NK cells primarily defend
against viral infections, tumors, and microbial species through cell-mediated cytolytic pro-
cesses involving perforin and granzyme molecules [116–119]. Although oxaliplatin treatment
caused mucosal injury, microbial dysbiosis, the proportion of NK cells remained unaffected.
Additionally, the presentation of DAMPs following oxaliplatin treatment does not appear the
affect the proportion of NK cells within the PPs and MLNs. A study investigating the effects of
oxaliplatin treatment on ovarian cancer cells has shown that this platinum-based drug
increases NK cell-mediated toxicity [120]. Analysis of NK cells in human peripheral blood of
patients receiving low-dose cisplatin and 5-fluorouracil treatment has also shown to prevent
NK cell suppression typically observed following colorectal surgery [121]. However, our data
suggests that NK cell-mediated cytotoxicity is an unlikely cause for enteric neuropathy follow-
ing oxaliplatin treatment. No immune cells infiltrated the myenteric plexus (determined by
pan-leukocyte CD45+ labelling), and thus, cell-mediated killing of neurons and glia is not
apparent.
γδ T cells are intraepithelial lymphocytes which act as immunosurveyers of the gastrointes-
tinal tract [122]. These cells account for upto 50% of intraepithelial lymphocytes within the
gastrointestinal tract and play a role in antigen presentation, anti-tumor immunity, microbial
defense, neutrophil and macrophage recruitment and cytokine production [123–125]. We did
not observe any changes in the proportion of γδ T cells in either the PPs or MLNs. Our data
suggests that they are not infiltrating lymphoid organs to present antigens following oxaliplatin
therapy, and that they are unlikely to be recruiting myeloid cells such as neutrophils and mac-
rophages given that no observable changes in MPO activity within the colon was found. One
study to date has demonstrated that oxaliplatin treatment induces infiltration of IL-17 produc-
ing γδ T cells to transplantable tumor sites [126]. It appears that oxaliplatin treatment can sen-
sitise cancer cells to specific γδ T cell-mediated immunity, but this seems unlikely for enteric
neurons, given that no infiltrating immune cells were observed.
B cells play an important role in intestinal immunity and mucosal tolerance. They are
enriched within gastrointestinal associated lymphoid organs, synthesise IgA which functions
to inhibit microbial adherence to mucosal surfaces, and neutralizes toxins, enzymes and anti-
gens [127]. B cells also induce T cell dependent or independent responses. An in vivo study has
shown that B cells can impede T cell responses characteristic of immunogenic cell death in
mouse tumor model [128]. In our study we did not observe any changes in the proportion of B
cells or various T cell subpopulations (CD4+, CD8+, NKT).
As there are a number of CD4+ T cell populations, such as Th1, Th2, Th9, Th17 and Tregs
[129], we analyzed them collectively to get an overview of CD4+ T cell proportions following
oxaliplatin treatment. CD4+ T cells influence innate and adaptive immune responses through
conditioning the milieu with pro-inflammatory or anti-inflammatory cytokines and
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chemokines [130]. Although NKT cells are a subset of CD4+ T cells they are activated through
CD1d-restricted lipid antigens as opposed to classical MHC class I and II molecules [131–
133]. The most extensively studied lipid ligand for CD1d is α-galactosylceramide [133]. Both
mammalian and bacterial lipids can stimulate NKT cells to stimulating rapid Th1 and Th2
responses. No changes were noted in the proportion of NKT cells within either the PPs or
MLNs following oxaliplatin treatment. However, the effects of oxaliplatin treatment on NKT
cells in vivo require further studies.
Furthermore, no demonstrable changes in the proportion of CD8+ T cells within the PPs or
MLNs were shown following oxaliplatin treatment. CD8+ T cells are activated upon antigen
presentation and can exert cytotoxic activity through two major pathways. These include the
granule exocytosis or the death receptor (TNF-α and Fas) pathway [134,135]. Previous studies
using peripheral blood and colon cancer cell lines have shown marked increases in T cell acti-
vation following the presentation of DAMPs induced by oxaliplatin treatment [28,136]. We
have previously demonstrated that oxaliplatin treatment evokes the presentation of DAMPs
within the myenteric plexus, however, no differences in T cell populations were observed.
Given that the gastrointestinal tract is constantly exposed to a myriad of antigens and path-
ogens, the local immune system has evolved over time to eradicate noxious stimuli through
non-inflammatory host-defense mechanisms [74]. These data suggest that chemotherapy-
induced microbiota dysbiosis, mucosal and neuronal damage in this case does not evoke
inflammation or immunogenic cell death, thus, ENS damage is most likely mediated through
direct drug toxicity.
Conclusion
This is the first study to determine the effects of oxaliplatin treatment on the gastrointestinal
microbiota and its effects on immune populations within the PPs and MLNs which mediate
local inflammation. Oxaliplatin treatment does not induce severe inflammation throughout
the thickness of the colon despite the presentation of DAMPs within in myenteric neurons.
These data are suggestive of antigen and microbial-specific tolerance. Thus, it appears that oxa-
liplatin treatment is not associated with inflammatory enteric neuropathy, and further research
is required to determine the mechanism of neuronal damage and death which contributes to
gastrointestinal dysfunction.
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